ReviewAesthetic plastic surgery2026
Efficiency of Tranexamic Acid for Prevention of Bleeding In Breast Surgery: A Systematic Review.
Review in Aesthetic plastic surgery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundHematoma and seroma formation are common postoperative complications following breast surgery that adversely affect both surgical outcomes and patient recovery. Tranexamic acid (TXA) is increasingly recognized as an effective prophylactic agent; however, evidence regarding its efficacy in breast surgery remains limited.
methodsThis systematic review aimed to evaluate the effect of perioperative TXA administration on postoperative outcomes in breast surgery. This review was conducted in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) 2020 guidelines. English-language databases were searched through March 2025 for randomized controlled trials and cohort studies evaluating the effect of TXA on postoperative outcomes in breast surgery, including hematoma formation, seroma formation, drain output and duration, and other adverse events.
resultsThirteen studies encompassing 3,496 patients were included. TXA demonstrated consistent benefits in mastectomy and breast reconstruction, significantly reducing drain output, seroma rates, and hematoma incidence. Drain output was reduced by 30-33% in several studies, with earlier drain removal reported. Results in reduction mammaplasty were inconsistent, with some studies reporting reduced hematoma and drainage and others showing no significant differences.
conclusionsTXA shows promise for reducing postoperative complications in breast surgery, particularly in mastectomy and reconstruction. Given its favorable safety profile, TXA should be considered as part of a comprehensive perioperative strategy. Further research is needed to establish optimal dosing protocols, especially for reduction mammaplasty. LEVEL OF EVIDENCE II: This journal requires that authors assign a level of evidence to each article. For a full description of these Evidence-Based Medicine ratings, please refer to the Table of Contents or the online Instructions to Authors www.springer.com/00266 .
Indexed as
Identifiers
42806124What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.